Chemistry42 runs on NVIDIA GPUs and utilizes NVIDIA CLARA
– a platform for imaging, genomics, patient monitoring, and drug discovery. It has been leveraged by over 20 pharmaceutical companies and over 15 external and 30 internal programs.
Using this generative AI system, Insilco generated a novel molecule for the treatment of idiopathic pulmonary fibrosis (IPF), a rare, chronic lung disease that causes progressive and irreversible decline in lung function. There are approximately 5 million people with IPF worldwide and the median survival is just 3 to 4 years.
The novel IPF drug recently received Orphan Drug Designation by the FDA and will soon be entering into Phase 2 trials with patients. It's a big milestone for AI drug discovery and the rare disease community – the first time a drug for a target discovered by AI and designed by AI has reached this stage.